Meeting
2013 ASCO Annual Meeting
Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts) with advanced (Adv) nonsquamous non-small cell lung cancer (NS-NSCLC).
Authors
Carrie Lee Marquette
University of Alabama at Birmingham, Birmingham, AL
Carrie Lee Marquette , Stefan C. Grant , Mollie DeShazo , Vishnu Reddy , Alan Cantor , Debi Miley , Mary Jerome , Francisco Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00655850
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8057)
DOI
10.1200/jco.2013.31.15_suppl.8057
Abstract #
8057
Poster Bd #
34E
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
First Author: Joshua E. Reuss
Poster
2023 ASCO Annual Meeting
A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.
First Author: Junli Xue
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2016 Gastrointestinal Cancers Symposium
Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.
First Author: Thomas John Semrad